Extranodal NK-T-cell lymphoma secondary prevention: Difference between revisions
(Created page with "__NOTOC__ {{Extranodal NK-T-cell lymphoma}} {{CMG}}; {{AE}} ==Overview== There are no established measures for the secondary prevention of [disease name]. OR Effective mea...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Extranodal NK-T-cell lymphoma}} | {{Extranodal NK-T-cell lymphoma}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{RG}} | ||
==Overview== | ==Overview== | ||
Effective measures for the secondary prevention of [ | Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include: [[Lactate dehydrogenase|LDH]] , [[MLH1|MLH]]1, PDGFRA, [[Vascular endothelial growth factor|VEGF]], [[PD-L1]], PD-1, [[Cyclin D1]], [[p53]], [[Ki-67]] | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include:<ref name="ZengHuang2019">{{cite journal|last1=Zeng|first1=Linshu|last2=Huang|first2=Wenting|last3=Cao|first3=Zheng|last4=Zheng|first4=Bo|last5=Liu|first5=Xiuyun|last6=Guo|first6=Lei|last7=Feng|first7=Xiaoli|title=The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage|journal=Annals of Hematology|volume=98|issue=6|year=2019|pages=1467–1476|issn=0939-5555|doi=10.1007/s00277-019-03643-9}}</ref> | |||
* [[Lactate dehydrogenase|LDH]] | |||
* [[MLH1]] | |||
* PDGFRA | |||
*[ | * [[Vascular endothelial growth factor|VEGF]] | ||
*[ | * [[PD-L1]] | ||
*[ | * PD-1 | ||
* [[Cyclin D1]] | |||
* [[p53]] | |||
* [[Ki-67]] | |||
==References== | ==References== | ||
Latest revision as of 13:14, 3 September 2019
|
Extranodal NK-T-cell lymphoma Microchapters |
|
Differentiating Extranodal NK-T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Extranodal NK-T-cell lymphoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma secondary prevention |
|
Extranodal NK-T-cell lymphoma secondary prevention in the news |
|
Risk calculators and risk factors for Extranodal NK-T-cell lymphoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include: LDH , MLH1, PDGFRA, VEGF, PD-L1, PD-1, Cyclin D1, p53, Ki-67
Secondary Prevention
Effective measures for the secondary prevention of extranodal NK-T-cell lymphoma include:[1]
References
- ↑ Zeng, Linshu; Huang, Wenting; Cao, Zheng; Zheng, Bo; Liu, Xiuyun; Guo, Lei; Feng, Xiaoli (2019). "The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage". Annals of Hematology. 98 (6): 1467–1476. doi:10.1007/s00277-019-03643-9. ISSN 0939-5555.